CA2840976A1 - Method for detection of amyloid beta oligomers in a fluid sample and uses thereof - Google Patents

Method for detection of amyloid beta oligomers in a fluid sample and uses thereof Download PDF

Info

Publication number
CA2840976A1
CA2840976A1 CA2840976A CA2840976A CA2840976A1 CA 2840976 A1 CA2840976 A1 CA 2840976A1 CA 2840976 A CA2840976 A CA 2840976A CA 2840976 A CA2840976 A CA 2840976A CA 2840976 A1 CA2840976 A1 CA 2840976A1
Authority
CA
Canada
Prior art keywords
antibody
oligomer
ndpoi
oligomers
bead
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2840976A
Other languages
English (en)
French (fr)
Inventor
Mary SAVAGE
Paul Shughrue
Abigail WOLFE
Alexander Mccampbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2840976A1 publication Critical patent/CA2840976A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
CA2840976A 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof Abandoned CA2840976A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
US61/507,332 2011-07-13
PCT/US2012/045886 WO2013009667A1 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Publications (1)

Publication Number Publication Date
CA2840976A1 true CA2840976A1 (en) 2013-01-17

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2840976A Abandoned CA2840976A1 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Country Status (13)

Country Link
US (2) US20130052670A1 (enExample)
EP (2) EP2732289B1 (enExample)
JP (1) JP2014521089A (enExample)
KR (1) KR20140072019A (enExample)
CN (1) CN103782171B (enExample)
AU (1) AU2012282825B2 (enExample)
BR (1) BR112014000671A2 (enExample)
CA (1) CA2840976A1 (enExample)
DK (1) DK2732289T3 (enExample)
ES (1) ES2666840T3 (enExample)
MX (1) MX2014000480A (enExample)
RU (1) RU2014105172A (enExample)
WO (2) WO2013009703A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3305302T (lt) 2009-06-17 2018-12-10 Biogen Ma Inc. Junginiai ir būdai smn2 splaisingo moduliavimui subjekte
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
KR20160079891A (ko) * 2013-11-20 2016-07-06 유니버시티 오브 아이오와 리써치 파운데이션 아밀로이드 침착의 치료를 위한 방법 및 조성물
EP3797780B1 (en) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
BR112017004056A2 (pt) * 2014-09-12 2017-12-05 Biogen Ma Inc composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
CA2994518C (en) * 2015-08-25 2025-05-06 Prothena Biosciences Limited METHODS FOR DETECTING PHOSPHORYLATED ALPHA-SYNUCLEIN
CN108603880B (zh) 2016-02-08 2021-01-05 希森美康株式会社 受试物质的检测方法及受试物质的检测用试剂盒
WO2017218884A1 (en) 2016-06-16 2017-12-21 Ionis Pharmaceuticals, Inc. Combinations for the modulation of smn expression
EP3995505A4 (en) * 2019-07-05 2023-07-26 Shimadzu Corporation MONOCLONAL ANTIBODY AGAINST AMYLOID BETA, AND METHOD FOR MEASURING AN AMYLOID BETA RELATED PEPTIDE USING THE SAME ANTIBODY
TW202517787A (zh) 2020-02-28 2025-05-01 美商Ionis製藥公司 用於調節smn2之化合物及方法
WO2022270901A1 (ko) * 2021-06-25 2022-12-29 장재원 동적 형광 또는 x-선의 표준편차와 자기상관을 활용한 조기 진단 시스템
US20240358805A1 (en) * 2021-08-30 2024-10-31 The Brigham And Women's Hospital, Inc. Methods and materials to treat neurodegenerative disease
EP4562427A2 (en) * 2022-07-27 2025-06-04 Durin Life Sciences, Inc. Early detection and monitoring of neurodegenerative diseases using a multi-disease diagnostic platform
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
WO2001010900A2 (en) 1999-08-04 2001-02-15 University Of Southern California Globular assembly of amyloid beta protein and uses thereof
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
JP4824547B2 (ja) 2004-02-20 2011-11-30 インテレクト ニュウロサイエンシス，インク． モノクローナル抗体およびその利用
WO2005096730A2 (en) * 2004-04-02 2005-10-20 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
EP1812062B1 (en) * 2004-10-25 2022-03-09 Merck Sharp & Dohme Corp. Anti-addl antibodies and uses thereof
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
CA2626783A1 (en) * 2005-10-21 2007-05-03 Merck & Co., Inc. Anti-addl monoclonal antibody and use thereof
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
JP2013511734A (ja) * 2009-11-24 2013-04-04 プロビオドルグ エージー アルツハイマー病又は軽度認知障害の診断のための新規診断方法
US8795664B2 (en) * 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2012009442A2 (en) * 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof

Also Published As

Publication number Publication date
EP2732286A1 (en) 2014-05-21
CN103782171B (zh) 2016-12-14
WO2013009667A1 (en) 2013-01-17
EP2732289B1 (en) 2018-04-11
EP2732289A2 (en) 2014-05-21
DK2732289T3 (en) 2018-05-22
US20130052670A1 (en) 2013-02-28
EP2732286A4 (en) 2015-02-25
ES2666840T3 (es) 2018-05-08
MX2014000480A (es) 2014-06-23
CN103782171A (zh) 2014-05-07
WO2013009703A8 (en) 2014-01-23
AU2012282825A1 (en) 2014-01-16
WO2013009703A3 (en) 2013-03-21
JP2014521089A (ja) 2014-08-25
RU2014105172A (ru) 2015-08-20
BR112014000671A2 (pt) 2017-02-14
AU2012282825B2 (en) 2016-05-26
KR20140072019A (ko) 2014-06-12
US20140120037A1 (en) 2014-05-01
WO2013009703A2 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
AU2012282825B2 (en) Method for detection of amyloid beta oligomers in a fluid sample and uses thereof
CA2584859C (en) Anti-addl antibodies and uses thereof
KR101706789B1 (ko) 진단용 항체 검사법
KR101461538B1 (ko) 생물학적 관심대상의 펩티드 및 단백질의 측정을 위한 고감도 면역검정법 및 키트
US9310383B2 (en) Antibodies, kit and method for detecting amyloid beta oligomers
JP2015514206A (ja) 抗ベータアミロイド抗体の検出に関する方法及びキット
JPWO2011045945A1 (ja) アミロイドβのターン構造を認識する抗体
US20250020669A1 (en) Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid
JP7151985B2 (ja) 抗プロパノイル化アミロイドβタンパク質抗体
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
US10295550B2 (en) Compositions and methods for use in diagnosis of alzheimer's disease
WO2026005695A1 (en) Detection of oligomeric tau and soluble tau aggregates
TW202344840A (zh) 診斷檢定
AU2011204912B2 (en) Anti-ADDL antibodies and uses thereof
TW201321409A (zh) 醫藥組合物
MX2007004909A (en) Anti-addl antibodies and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180710